Payers Partnerships for DTx

Digital Therapeutics (DTx) vendors face many challenges on their journey to commercialization, such as generating clinical data, health economics evidence and achieving regulatory status. Beyond that, finding a way to show value to get paid is extremely difficult, which slows down DTx adoption and revenue growth. Many DTx vendors decide to target private and public payers as a way to get reimbursed. However, the process is not as straightforward as it is for drugs and it is critical to have a good understanding of the different archetypes to have a more focused and effective market access strategy. Join this session to have a peer-to-peer conversation about: